Antithrombotic P2Y12 receptor antagonists

recent developments in drug discovery

Younis Baqi, Christa E. Müller

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The P2Y12 receptor is one of eight known P2Y receptor subtypes, and belongs to the G-protein-coupled receptor (GPCR) family. The P2Y12 receptor is highly expressed on blood platelets and in the brain. Potent, selective, peripherally acting antagonists for the P2Y12 receptor are used clinically as antithrombotic drugs. Several different scaffolds have been identified as P2Y12 receptor antagonists, including irreversibly acting thienotetrahydropyridines (prodrugs), and reversible competitive antagonists, including adenine nucleotide analogs, piperazinyl-glutamate-quinolines, -pyridines, and -pyrimidines, and anthraquinone derivatives. Here, we provide an overview of the different scaffolds that have been developed as P2Y12 receptor antagonists, some of which have become important therapeutics.

Original languageEnglish
JournalDrug Discovery Today
DOIs
Publication statusAccepted/In press - Jan 1 2018

Fingerprint

Purinergic P2Y Receptor Antagonists
Drug Discovery
Quinolines
Pyridines
Anthraquinones
Pyrimidines
Adenine Nucleotides
Prodrugs
G-Protein-Coupled Receptors
Glutamic Acid
Blood Platelets
Brain
Pharmaceutical Preparations
Therapeutics

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Cite this

Antithrombotic P2Y12 receptor antagonists : recent developments in drug discovery. / Baqi, Younis; Müller, Christa E.

In: Drug Discovery Today, 01.01.2018.

Research output: Contribution to journalArticle

@article{f2bcd2a82d084080a95e84d8e2c60805,
title = "Antithrombotic P2Y12 receptor antagonists: recent developments in drug discovery",
abstract = "The P2Y12 receptor is one of eight known P2Y receptor subtypes, and belongs to the G-protein-coupled receptor (GPCR) family. The P2Y12 receptor is highly expressed on blood platelets and in the brain. Potent, selective, peripherally acting antagonists for the P2Y12 receptor are used clinically as antithrombotic drugs. Several different scaffolds have been identified as P2Y12 receptor antagonists, including irreversibly acting thienotetrahydropyridines (prodrugs), and reversible competitive antagonists, including adenine nucleotide analogs, piperazinyl-glutamate-quinolines, -pyridines, and -pyrimidines, and anthraquinone derivatives. Here, we provide an overview of the different scaffolds that have been developed as P2Y12 receptor antagonists, some of which have become important therapeutics.",
author = "Younis Baqi and M{\"u}ller, {Christa E.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.drudis.2018.09.021",
language = "English",
journal = "Drug Discovery Today",
issn = "1359-6446",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Antithrombotic P2Y12 receptor antagonists

T2 - recent developments in drug discovery

AU - Baqi, Younis

AU - Müller, Christa E.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - The P2Y12 receptor is one of eight known P2Y receptor subtypes, and belongs to the G-protein-coupled receptor (GPCR) family. The P2Y12 receptor is highly expressed on blood platelets and in the brain. Potent, selective, peripherally acting antagonists for the P2Y12 receptor are used clinically as antithrombotic drugs. Several different scaffolds have been identified as P2Y12 receptor antagonists, including irreversibly acting thienotetrahydropyridines (prodrugs), and reversible competitive antagonists, including adenine nucleotide analogs, piperazinyl-glutamate-quinolines, -pyridines, and -pyrimidines, and anthraquinone derivatives. Here, we provide an overview of the different scaffolds that have been developed as P2Y12 receptor antagonists, some of which have become important therapeutics.

AB - The P2Y12 receptor is one of eight known P2Y receptor subtypes, and belongs to the G-protein-coupled receptor (GPCR) family. The P2Y12 receptor is highly expressed on blood platelets and in the brain. Potent, selective, peripherally acting antagonists for the P2Y12 receptor are used clinically as antithrombotic drugs. Several different scaffolds have been identified as P2Y12 receptor antagonists, including irreversibly acting thienotetrahydropyridines (prodrugs), and reversible competitive antagonists, including adenine nucleotide analogs, piperazinyl-glutamate-quinolines, -pyridines, and -pyrimidines, and anthraquinone derivatives. Here, we provide an overview of the different scaffolds that have been developed as P2Y12 receptor antagonists, some of which have become important therapeutics.

UR - http://www.scopus.com/inward/record.url?scp=85054683455&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054683455&partnerID=8YFLogxK

U2 - 10.1016/j.drudis.2018.09.021

DO - 10.1016/j.drudis.2018.09.021

M3 - Article

JO - Drug Discovery Today

JF - Drug Discovery Today

SN - 1359-6446

ER -